Please login to the form below

Not currently logged in

Caligor Rx appoints Michael Dallmann as director of strategic planning

He brings experience from Cubist Pharmaceuticals and Peninsula Pharmaceuticals

New Jersey-based Caligor Rx has named Michal Dallman to the newly-created role of as director of strategic planning.

In this position he will be responsible for developing and driving the drug sourcing company's portfolio, including its comparator programmes.

Michael Dallmann: “Through its comparator programmes, Caligor has established an outstanding global reputation marked by the depth of its regulatory expertise, the strength of its relationships with manufacturers and suppliers and the quality of its values. 

“I am delighted to join Caligor and look forward to helping to shape and execute the company's long-term strategic objectives … it's a privilege to be part of this growing organisation.”

Dallmann - who has over two decades of pharmaceutical experience - moves to Caligor from Cubist Pharmaceuticals, which he joined as director of global clinical trial supply in 2013.

Prior to this he also served as associate director of research and development project planning for Peninsula Pharmaceuticals, a Johnson & Johnson company.

Tammy Bishop, Caligor managing director, said: “Mike is an experienced leader who brings the ideal complement of strategic skills to support our growing business.

“His international product development background and the strong relationships he has established over more than two decades in the life sciences industry will serve us well as we continue to expand our services across Europe and Asia.”

5th January 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?